<DOC>
	<DOCNO>NCT00493766</DOCNO>
	<brief_summary>This parallel , two-arm , open-label , multicenter phase IA/IB study LBH589 ( oral formulation ) alone combination docetaxel patient progress hormone refractory prostate cancer . This study design determine maximum tolerate dose LBH589 single agent combination docetaxel prednisone 5 mg two time day , characterize safety , tolerability , biologic activity pharmacokinetic profile</brief_summary>
	<brief_title>Safety LBH589 Alone Combination With IV Docetaxel Prednisone</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Inclusion criterion : Histologically document adenocarcinoma prostate . Patients must metastatic disease least one measurable soft tissue lesion assess computerized tomography ( CT ) , magnetic resonance imaging ( MRI ) and/or detectable lesion ( ) bone scintigraphy scan . Patients elevate prostate specific antegen ( PSA ) level eligible entry . Patients undergone medical castration must continue Luteinizing hormonereleasing hormone ( LHRH ) agonist antagonist therapy study treatment Patients must able provide write informed consent Exclusion criterion : Patients prior concurrent brain metastasis Impaired cardiac , gastrointestinal , kidney , liver function Use therapeutic androgen Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>LBH589</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>HRPC</keyword>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
</DOC>